FDA Accepts Application for New Glioma Imaging Agent

The U.S. Food and Drug Administration has accepted a New Drug Application for 18F-FET, a PET imaging agent. If approved, this agent, known as Pixclara or TLX101-Px, would be used to assess patients with suspected or confirmed gliomas. This development could provide a more precise method for mapping tumor boundaries and monitoring treatment response compared to current standard MRI techniques.